Related Experiment Video
Updated: May 17, 2025
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Common Mutations: New Strategies
Brigida Stanzione1, Alessandro Del Conte1, Elisa Bertoli1
1Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.
Abstract:
Epidermal growth factor receptor (EGFR) mutations are described in 10-15% of Caucasian patients and in 50% of Asian patients with non-squamous non-small cell lung cancer (NSCLC). The introduction of tyrosine kinase inhibitors (TKIs) has revolutionized the therapeutic scenario and has changed the natural history of the disease. Despite the results obtained with osimertinib, a third-generation TKI, most patients experience disease progression. The search for new therapeutic strategies both to enhance first-line treatment and to ensure adequate second-line therapies represents an unmet medical need, towards which all efforts are being concentrated. In this review, we describe the main strategies identified to improve the prognosis of patients with EGFR-mutated NSCLC.
Insights
Epidermal growth factor receptor (EGFR) mutations drive non-small cell lung cancer (NSCLC). New strategies are needed to overcome resistance to targeted therapies like osimertinib and improve patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
Background:
- Epidermal growth factor receptor (EGFR) mutations are key drivers in non-small cell lung cancer (NSCLC), particularly in Asian populations.
- Tyrosine kinase inhibitors (TKIs) have transformed NSCLC treatment, but disease progression remains a significant challenge.
Purpose of the Study:
- To review current strategies for improving prognosis in patients with EGFR-mutated NSCLC.
- To address the unmet need for enhanced first-line and effective second-line therapies.
Main Methods:
- Literature review of therapeutic strategies for EGFR-mutated NSCLC.
- Analysis of treatment advancements and unmet needs in NSCLC management.
Main Results:
- Osimertinib, a third-generation TKI, shows efficacy but is followed by disease progression in most patients.
- Identification of novel therapeutic avenues to enhance existing treatments and establish robust second-line options.
Conclusions:
- Improving the prognosis of EGFR-mutated NSCLC requires innovative approaches beyond current TKIs.
- Further research into combination therapies and novel agents is crucial to overcome treatment resistance and prolong survival.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
15:05Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...